Literature DB >> 9607061

Intradermal DNA immunization of mice against influenza A virus using the novel PowderJect system.

P Dégano1, D F Sarphie, C R Bangham.   

Abstract

The PowderJect system, a device that uses compressed helium gas to accelerate microscopic particles into the skin, was used as a delivery system for DNA vaccines to elicit a virus-specific cytotoxic T cell response (CTL) in mice. Transient expression of beta-galactosidase (beta-Gal) was observed in the epidermis when gold particles coated with beta-Gal expression plasmid were delivered to mouse skin with the device. When DNA encoding the nucleoprotein gene (NP) of influenza A virus was used to coat gold particles, a strong and specific anti-NP CTL response was elicited by immunizations with nanogram amounts of the NP DNA vector. This study shows the potential for application of the PowderJect system to intradermal delivery of DNA in order to elicit an immune response.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9607061     DOI: 10.1016/s0264-410x(97)00202-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

Review 1.  DNA-antiviral vaccines: new developments and approaches--a review.

Authors:  M Giese
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

Review 2.  DNA and RNA-based vaccines: principles, progress and prospects.

Authors:  W W Leitner; H Ying; N P Restifo
Journal:  Vaccine       Date:  1999-12-10       Impact factor: 3.641

Review 3.  Transdermal drug delivery of insulin with ultradeformable carriers.

Authors:  Gregor Cevc
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 4.  Needle free injection technology: A complete insight.

Authors:  Ansh Dev Ravi; D Sadhna; D Nagpaal; L Chawla
Journal:  Int J Pharm Investig       Date:  2015 Oct-Dec

5.  Novel ethanol-in-fluorocarbon microemulsions for topical genetic immunization.

Authors:  Zhengrong Cui; William Fountain; Michael Clark; Michael Jay; Russell J Mumper
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.